Harrow Inc (HROW) Stock AnalysisHROWHarrow Inc

Harrow, Inc. is a provider of ophthalmic disease management solutions. It offers a portfolio of products that address conditions affecting both the front and back of the eye, such as dry eye disease, wet age-related macular degeneration, cataracts, refractive errors, glaucoma and a range of other ocular surface conditions and retina diseases. It owns commercial rights to portfolios of branded ophthalmic pharmaceutical products in the United States, all of which are marketed under the Harrow name. It owns and operates ImprimisRx, an ophthalmology-focused pharmaceutical-compounding business. It owns United States commercial rights to various products: IHEEZO, VEVYE, TRIESENCE, VIGAMOX, FLAREX, NATACYN, BYQLOVI and others. Its development-stage programs include MELT-300, H-N08, CR-01, and MELT-210. VIGAMOX (moxifloxacin hydrochloride ophthalmic solution) 0.5%, a fluoroquinolone antibiotic eye drops for the treatment of bacterial conjunctivitis caused by susceptible strains of organisms. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Harrow, Inc. appears to be a good buy right now due to its current price of $28.44, which is significantly lower than analyst price targets that suggest potential upside of 86% to $71. The company reported a gross margin of 71.27% in Q2 2026, indicating strong profitability, despite recent challenges. However, the main risk is the high debt-to-equity ratio of 1969.55%, which poses a financial risk if market conditions worsen.